We also report that upregulation of TRPV1 alleviates AD‐related neuropathologies and inhibits AMPAR endocytosis via interacting with GluA2 subunit, which may subsequently contribute to the amelioration of cognitive function and synaptic plasticity. Here, GRIA2 is linked to Alzheimer disease.